Growth Amid Decline

The company's guidance for 2026 indicates a forecasted high single‑digit percentage decline in low molecular weight heparin sales, primarily due to market competition. Despite these challenges, ROVI is investing in vertical integration to remain competitive and expects the business to continue growing in the long term. The company's expansion into new prefilled syringe manufacturing agreements and its commitment to R&D investments demonstrate its focus on growth and innovation.